ATI355
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Spinal Cord Injury
Conditions
Acute Spinal Cord Injury
Trial Timeline
May 1, 2006 → Sep 1, 2011
NCT ID
NCT00406016About ATI355
ATI355 is a phase 1 stage product being developed by Novartis for Acute Spinal Cord Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT00406016. Target conditions include Acute Spinal Cord Injury.
What happened to similar drugs?
20 of 20 similar drugs in Acute Spinal Cord Injury were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00406016 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Spinal Cord Injury